Claim In proliferative lupus nephritis, the joint rate of change in complement recovery (especially C3) and UPCR decline over the first 8-12 weeks of induction therapy will classify 6-month renal response more accurately than single-visit threshold definitions alone.

Rationale Most treatment-response frameworks emphasize whether the patient crosses a proteinuria or creatinine threshold at a fixed visit. That approach may miss clinically informative kinetics: two patients with the same week-12 UPCR may have very different trajectories if one is improving rapidly with recovering complement and the other is flat or worsening. A dynamic slope-based model may better separate true responders, delayed responders, and patients who need earlier treatment reassessment.

Testable design

• Prospective lupus nephritis induction cohort with measurements at baseline, weeks 4, 8, 12, and month 6.
• Variables: UPCR, creatinine/eGFR, C3, C4, anti-dsDNA, BP, induction regimen, and adherence.
• Compare models for month-6 complete/partial/non-response:
  1. fixed week-12 threshold model
  2. UPCR slope model
  3. complement-recovery slope + UPCR slope model
  4. full joint dynamic model with baseline chronicity/activity adjustment
• Primary metrics: AUROC, calibration slope, decision-curve net benefit.

Falsification The hypothesis is weakened if slope-based models fail to improve discrimination or calibration beyond simpler fixed-threshold definitions.

Why it matters If true, response assessment could move earlier and become more kinetic, helping identify under-responders before avoidable renal injury accumulates.

References

1. Dall'Era M, Cisternas MG, Smilek DE, et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons from the ALMS study. Ann Rheum Dis. 2015;74(6):1125-1130. DOI: 10.1136/annrheumdis-2013-205102
2. Rovin BH, Solomons N, Pendergraft WF, et al. AURORA 1: voclosporin in active lupus nephritis. Lancet. 2021;397(10289):2070-2080. DOI: 10.1016/S0140-6736(21)00578-X
3. Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 update of the joint EULAR/ERA-EDTA recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713-723. DOI: 10.1136/annrheumdis-2020-216924